Page last updated: 2024-12-06

nilverm

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID68628
CHEMBL ID554891
CHEBI ID9496
SCHEMBL ID44230
MeSH IDM0021245

Synonyms (123)

Synonym
smr000058395
MLS000028416
imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (+-)-
(+-)-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole monohydrochloride
citarin (van)
orovermol
dl-6-phenyl-2,3,5,6-tetrahydroimidazole(2,1-b)thiazole-hydrochloride
mcn-jr-8299
bayer 9051
tetramisole hydrochloride [usan]
nsc 170985
einecs 225-799-5
EU-0101194
tetramisole hydrochloride, phosphatase inhibitor
PRESTWICK_854
tetramisole hydrochloride (usan)
D06091
(+-)-tetramisole hydrochloride
5086-74-8
tetramisole hydrochloride
citarin
pig wormer
r 8299
2,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride
nsc-170985
mcn-jr-8299-11
nsc170985
nilverm
tetramisol hydrochloride
imidazo[2, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (.+-.)-
nsc-215179
(.+-.)-tetramisole hydrochloride
dl-tetramisole hydrochloride
nsc215179
ascarotrat
mcn jr 8299
solaskil hydrochloride
4641-34-3
nilverom
anthelvet
ripereol
dl-6-phenyl-2,5,6-tetrahydroimidazole[2,1-b]thiazole-hydrochloride
rp 16535
(.+-.)-anthelvet
mcnjr8299
(.+-.)-2,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole monohydrochloride
ripercol
concurat
wln: t55 an dn fs dutj cr &gh -r
NCGC00094446-02
NCGC00094446-01
NCGC00094446-04
NCGC00094446-05
T 1512
( inverted question mark)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride
chebi:9496 ,
CHEMBL554891
levamisole dl-form hydrochloride
tetramisole hydrochloride, dl-
BMK1-H7
tetramisole hcl
6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole hydrochloride
FT-0659999
HMS1569N11
unii-0ndk265mcv
0ndk265mcv ,
6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole hydrochloride
A828325
nsc-758437
pharmakon1600-01503245
nsc-759175
nsc758437
nsc759175
pharmakon1600-01505679
S4094
FT-0625516
LP01194
AKOS015900432
(+/-)-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazole monohydrochloride
tetramisole hydrochloride [who-dd]
tetramisole hydrochloride [mart.]
levamisole dl-form hydrochloride [mi]
imidazo(2,1-b)thiazole, 2,3,5,6-tetrahydro-6-phenyl-, monohydrochloride, (+/-)-
CCG-213508
CCG-220545
CCG-222498
SCHEMBL44230
HS-0026
T3663
CS-4801
tox21_501194
NCGC00261879-01
dl tetramisole hydrochloride
LAZPBGZRMVRFKY-UHFFFAOYSA-N
methyl4-methoxy-3-nitrobenzoate
W-105926
tetramisole (hydrochloride) ,
AC-22590
HY-B1194
( inverted exclamation marka)-tetramisole hydrochloride
r-829
sr-01000076148
SR-01000076148-1
tetramisole hydrochloride, vetranal(tm), analytical standard
SR-01000076148-5
mfcd00005536
FT-0670770
5086-74-8, 5036-02-2(free base)
ergamisol hydrochloride
Q27108410
DTXSID101017245
SB18744
AMY40516
(+/-)-tetramisole hydrochloride;dl-tetramisole hydrochloride;r-829
ashitetra; duxamintic
6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole;hydrochloride
D70698
()-tetramisole hydrochloride;dl-tetramisole hydrochloride;r-829
(+/-)-2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole hydrochloride
6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazolehydrochloride
imidazo[2,1-b]thiazole, 2,3,5,6-tetrahydro-6-phenyl-, hydrochloride (1:1)
EN300-296086
6-phenyl-2h,3h,5h,6h-imidazo[2,1-b][1,3]thiazole hydrochloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
endonuclease IVEscherichia coliPotency5.01190.707912.432431.6228AID1708
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency44.66840.011212.4002100.0000AID1030
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency7.94330.28189.721235.4813AID2326
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency35.71280.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency95.283423.934123.934123.9341AID1967
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
gemininHomo sapiens (human)Potency0.00460.004611.374133.4983AID624296
M-phase phosphoprotein 8Homo sapiens (human)Potency50.11870.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency2.51190.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
corticotropin-releasing hormone receptor 2Homo sapiens (human)IC50 (µMol)47.10000.36807.095518.0000AID602180
corticotropin releasing factor-binding proteinHomo sapiens (human)IC50 (µMol)47.10000.36807.095518.0000AID602180
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
corticotropin-releasing hormone receptor 2Homo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
corticotropin releasing factor-binding proteinHomo sapiens (human)EC50 (µMol)53.00001.120011.561736.8000AID602473
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (27)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID204590Anthelmintic activity (in Vivo)in sheep as percentage reduction versus control (by administration of benzimidazole-susceptible L3 larvae of Haemonchus contortus intraruminally)at 7.5 mg/kg po1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and anthelmintic activity of 3'-benzoylurea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole.
AID1130640Inhibition of alkaline phosphatase in mouse 180/TG cells assessed as p-nitrophenyl phosphate hydrolysis by spectrophotometry1979Journal of medicinal chemistry, Sep, Volume: 22, Issue:9
Synthesis and biological evaluation of tetramisole analogues as inhibitors of alkaline phosphatase of the 6-thiopurine-resistant tumor sarcoma 180/TG.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1132880Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 104 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1132881Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 52 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID204728Anthelmintic activity (in Vivo)in sheep as percentage reduction versus control (by administration of benzimidazole-susceptible L3 larvae of Ostertagia circumcincta intraruminally)at 7.5 mg/kg po1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and anthelmintic activity of 3'-benzoylurea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole.
AID204738Anthelmintic activity (in Vivo)in sheep as percentage reduction versus control (by administration of benzimidazole-susceptible L3 larvae of Trichostrongylus colubriformis intraruminally) at 7.5 mg/kg po1991Journal of medicinal chemistry, May, Volume: 34, Issue:5
Synthesis and anthelmintic activity of 3'-benzoylurea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole.
AID1132883Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 13 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (13.33)18.7374
1990's1 (6.67)18.2507
2000's3 (20.00)29.6817
2010's7 (46.67)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 49.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index49.84 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.09 (4.65)
Search Engine Demand Index73.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (49.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]